Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, tolerability, and pharmacokinetics study of CEP-37248 in healthy men
NL-OMON40424Phase 1Active, not recruiting
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Aug 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of CEP-37248 in autoimmune inflammatory diseases, autoimmune colitis and Crohn's disease, sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoints: Safety and Tolerability. Started Aug 2013; status: active, not recruiting.
02
Drugs
CEP-37248
03
Conditions
autoimmune inflammatory diseasesautoimmune colitisCrohn's disease
Beyond the preview
Go deeper on NL-OMON40424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40424.